作者: 小口啜飲 時(shí)間: 2025-3-21 22:36
Anti-Apoptotic Bcl-2,hway. Approximately 25 members of the BCL-2 family have been grouped into three categories based on structure and function: (1) anti- apoptotic, (2) pro-apoptotic, and (3) BH3 only proteins. This chapter will focus on a family of five anti-apoptotic proteins: (1) BCL-2, (2) BCL-xL, (3) BCL-w, (4) MC作者: mighty 時(shí)間: 2025-3-22 03:24 作者: 期滿 時(shí)間: 2025-3-22 05:50 作者: 藐視 時(shí)間: 2025-3-22 08:46
Anti-Idiotype Antibodies,ed to as the “idiotype” (Id), is composed of the unique antigenic determinants in the variable regions of the clonal Ig heavy and light chains expressed by the tumor cells (Timmerman and Levy 2000). This protein target has the unusual nature of being unique in every B-cell cancer (Fig. 1). The human作者: motor-unit 時(shí)間: 2025-3-22 16:47 作者: motor-unit 時(shí)間: 2025-3-22 18:43
APC,s a critical suppressor of cancer initiation. Individuals who inherit inactivating mutations in one allele of the . gene exhibit familial adenomatous polyposis (FAP) coli, an autosomal dominant syndrome characterized by the formation of a variety of benign lesions, particularly numerous adenomatous 作者: Dictation 時(shí)間: 2025-3-22 23:20 作者: arrhythmic 時(shí)間: 2025-3-23 02:00 作者: dermatomyositis 時(shí)間: 2025-3-23 05:51 作者: WAG 時(shí)間: 2025-3-23 09:42
B7.1,id tumors (Lenschow et al. 1996). Nevertheless, B7-1 has been shown to be essential for the induction of T-cell responses, which play a central role in mediating tumor immunosurveillance and immune-mediated tumor regression (Ward and Kaufman 2007). B7-1 consequently plays an important role in cancer作者: tenosynovitis 時(shí)間: 2025-3-23 17:32
Bacterial Vaccines,rplay, as well as the recent advances in genetic engineering. Safe, targeted therapies are being developed, in which genetically-modified pathogens are designed to trigger effective anti-tumor immune response. Here we describe the bacterial strains intended for cancer immunotherapies, the genetic mo作者: 周年紀(jì)念日 時(shí)間: 2025-3-23 19:10
BH3-Only Mimetics,specific groove of anti-apoptotic Bcl-2 family survival factors in a similar manner to native proteins within the cell that regulate these factors. This primes the cell for apoptosis. Several small molecule BH3 mimetics are currently undergoing evaluation in clinical trials.作者: 壯麗的去 時(shí)間: 2025-3-23 22:58 作者: Commonplace 時(shí)間: 2025-3-24 05:29
BRCA1 and 2,ion to breast cancer, and BRCA2 additionally predisposes to ovarian cancer. Women who carry high-risk BRCA1 mutant alleles have a 50–85 % chance of developing breast cancer by age 70 years. Differences in cancer risk estimates appear to be due to the extent of family history, with a strong family hi作者: tenosynovitis 時(shí)間: 2025-3-24 07:44 作者: GRAIN 時(shí)間: 2025-3-24 11:43
CCL21, tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer作者: 暫時(shí)中止 時(shí)間: 2025-3-24 16:09
CD4+ T Cells, cytokines and expression of distinct intracellular transcription factors and surface chemokine receptors. The functional diversity of T cells is demonstrated by the association of certain CD4+ T cell types (including Th1 CD4+ T cells) with positive cancer prognosis and other CD4+ T cell types (incl作者: 開頭 時(shí)間: 2025-3-24 22:57 作者: 倔強(qiáng)一點(diǎn) 時(shí)間: 2025-3-25 00:02
S. Roussos,C. R. Soccol,C. AugurUpon reactivation of AR-FL and expression of AR-Vs, traditional methods of treatment targeting the ligand binding domain are ineffective. Targeting the evolutionarily conserved N-terminal domain, DNA binding domain (DBD) or using transcription factors that interact with AR will be key in developing new treatments for PCa.作者: reptile 時(shí)間: 2025-3-25 04:55
AR, Overview,Upon reactivation of AR-FL and expression of AR-Vs, traditional methods of treatment targeting the ligand binding domain are ineffective. Targeting the evolutionarily conserved N-terminal domain, DNA binding domain (DBD) or using transcription factors that interact with AR will be key in developing new treatments for PCa.作者: Vital-Signs 時(shí)間: 2025-3-25 11:03 作者: correspondent 時(shí)間: 2025-3-25 13:22 作者: exclusice 時(shí)間: 2025-3-25 17:44
B-Raf, cancers. It is believed to be an early event since it is seen in the majority of nevi and a subset of premalignant colon polyps. Several kinase inhibitors targeting B-Raf are approved for advanced melanoma.作者: VAN 時(shí)間: 2025-3-25 20:35 作者: bleach 時(shí)間: 2025-3-26 01:28
CCL21,. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.作者: 媽媽不開心 時(shí)間: 2025-3-26 07:27 作者: modest 時(shí)間: 2025-3-26 09:53 作者: 藥物 時(shí)間: 2025-3-26 13:16 作者: 博愛家 時(shí)間: 2025-3-26 17:47 作者: preeclampsia 時(shí)間: 2025-3-27 00:46
Novelty-Based Multiobjectivization. Recent clinical trials using both purified tumor infiltrating lymphocytes (TILs) as well as the novel chimeric antigen receptor T cells (CAR T cells) have shown great promise in the treatment of a variety of neoplasias including melanoma, and leukemias. Many clinical trials are now ongoing to elucidate the potential of these new therapies.作者: 不透明 時(shí)間: 2025-3-27 04:34
Anti-B7-H4,7-H4 up-regulation has shown to be associated with diseases progression and/or outcome in some cancers. The unique expression of B7-H4 in the tumor microenvironment and its potential immune inhibitory functions on both innate and adaptive immune responses represents a novel target for the next-generation cancer diagnosis and immunotherapy.作者: correspondent 時(shí)間: 2025-3-27 06:41
Anti-Programmed Death 1 (PD1), in reduced T-cell activation and effector function (Okazaki and Honjo 2007; Keir et al. 2008). The PD-1 ligand PD-L1 is expressed on many tumors and is an important component of the immunosuppressive tumor microenvironment (Brown et al. 2003; Dong et al. 2002; Driessens et al. 2009; Wang n.d.).作者: mighty 時(shí)間: 2025-3-27 10:35 作者: Pde5-Inhibitors 時(shí)間: 2025-3-27 17:13
CD8 T Cells,. Recent clinical trials using both purified tumor infiltrating lymphocytes (TILs) as well as the novel chimeric antigen receptor T cells (CAR T cells) have shown great promise in the treatment of a variety of neoplasias including melanoma, and leukemias. Many clinical trials are now ongoing to elucidate the potential of these new therapies.作者: 制定 時(shí)間: 2025-3-27 21:49 作者: 蝕刻術(shù) 時(shí)間: 2025-3-27 23:39
Recent Generative Studies in Chinese Syntax, therapies in a wide variety of cancers. In this review, we describe the biology of AXL, review diverse mechanisms of activation and the established and putative roles of AXL as a biomarker and therapeutic target in cancer therapy. Pre-clinical and clinical data for anti-AXL therapies to date are also summarized.作者: Hyperlipidemia 時(shí)間: 2025-3-28 05:08
New Horizons in Chinese Linguistics cancers. It is believed to be an early event since it is seen in the majority of nevi and a subset of premalignant colon polyps. Several kinase inhibitors targeting B-Raf are approved for advanced melanoma.作者: 緩和 時(shí)間: 2025-3-28 09:09 作者: heterogeneous 時(shí)間: 2025-3-28 13:29
Miloslava Plachkinova,Ken Peffers,Greg Moody. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.作者: GRIN 時(shí)間: 2025-3-28 18:16
Radio Continuum Surveys Above 2 GHze other members of the tumor necrosis factor superfamily, the ecto-domain of 4-1BB forms a homotrimer with an extended, three-bladed propeller structure (Won et al. 2010). 4-1BB also has a cysteine-rich extracellular domain, a transmembrane region, and a cytoplasmic domain that contains a tyrosine kinase p56. binding site (Vinay and Kwon 2006).作者: FECT 時(shí)間: 2025-3-28 18:53
Radio Continuum Surveys Above 2 GHzs with melanoma having the best outcomes, with a minority of patients having some responses. Cytokine release syndrome was the most common adverse event. Rational combinations of cytokines with the use of novel immunotherapies targeting CD40 may show promise in the treatment of neoplastic disease.作者: 王得到 時(shí)間: 2025-3-29 00:56 作者: 伸展 時(shí)間: 2025-3-29 04:41 作者: GLADE 時(shí)間: 2025-3-29 10:24
Anti-CD40/Anti-CD40L,s with melanoma having the best outcomes, with a minority of patients having some responses. Cytokine release syndrome was the most common adverse event. Rational combinations of cytokines with the use of novel immunotherapies targeting CD40 may show promise in the treatment of neoplastic disease.作者: Chivalrous 時(shí)間: 2025-3-29 11:38
BRCA1 and 2,equencies. Synthetic lethality studies have identified BRCA1 and BRCA2 mutations as conferring therapeutic sensitivity to PARP inhibitors. In addition, these mutations confer sensitivity to platinum salts.作者: 精美食品 時(shí)間: 2025-3-29 18:08 作者: 財(cái)主 時(shí)間: 2025-3-29 23:25 作者: Occlusion 時(shí)間: 2025-3-30 02:32
Radio Continuum Surveys Above 2 GHzse concanavalin A-activated helper and cytotoxic T-cell lines (Vinay and Kwon 2006). It was then isolated from PMA plus ionomycin-treated human peripheral T-cell cDNA libraries (Zhou et al. 1995). In humans, 4-1BB maps to chromosome 19p13.3 (Alderson et al. 1994). It is also commonly referred to as 作者: 蛤肉 時(shí)間: 2025-3-30 06:31 作者: 使更活躍 時(shí)間: 2025-3-30 11:00 作者: 排他 時(shí)間: 2025-3-30 12:51
Radio Continuum Surveys Above 2 GHzare associated with increased angiogenesis and systemic inflammation. High levels of the ligand alone are also associated with poorer tumor outcomes. However, increased levels of both the ligand and receptor are associated with increased tumor antigen presentation by antigen presenting cells and hav作者: 拾落穗 時(shí)間: 2025-3-30 20:36 作者: 否決 時(shí)間: 2025-3-31 00:28
New Horizons in Allergy Immunotherapy07; Keir et al. 2008). Upon ligand binding, PD-1 delivers an inhibitory signal that attenuates T-cell receptor (TCR) signaling. PD-1 signaling results in reduced T-cell activation and effector function (Okazaki and Honjo 2007; Keir et al. 2008). The PD-1 ligand PD-L1 is expressed on many tumors and 作者: Circumscribe 時(shí)間: 2025-3-31 03:26
https://doi.org/10.1007/978-94-017-0203-4s a critical suppressor of cancer initiation. Individuals who inherit inactivating mutations in one allele of the . gene exhibit familial adenomatous polyposis (FAP) coli, an autosomal dominant syndrome characterized by the formation of a variety of benign lesions, particularly numerous adenomatous 作者: Obituary 時(shí)間: 2025-3-31 06:17
S. Roussos,C. R. Soccol,C. AugurPCa). AR is the initial target for treatment in hormone dependent PCa, where inhibition of AR activity results in a decrease in tumor volume and increased survival. However, PCa often returns as castration-resistant prostate cancer (CRPC) due to several factors including AR overexpression, reactivat作者: 懶鬼才會(huì)衰弱 時(shí)間: 2025-3-31 11:43 作者: 補(bǔ)角 時(shí)間: 2025-3-31 15:50 作者: 新字 時(shí)間: 2025-3-31 18:54 作者: 針葉樹 時(shí)間: 2025-4-1 01:16 作者: GIDDY 時(shí)間: 2025-4-1 02:50
Chiara Francalanci,Ajaz Hussainspecific groove of anti-apoptotic Bcl-2 family survival factors in a similar manner to native proteins within the cell that regulate these factors. This primes the cell for apoptosis. Several small molecule BH3 mimetics are currently undergoing evaluation in clinical trials.作者: transplantation 時(shí)間: 2025-4-1 09:04 作者: Galactogogue 時(shí)間: 2025-4-1 11:29 作者: 浮雕 時(shí)間: 2025-4-1 14:25
Brian Donnellan,Markus Helfert,Robert Winterlation of apoptosis is a fundamental component of some tumors. At least 15 caspases have been identified. Mutations and polymorphisms of caspase genes have been described in several solid tumors, and these mutations may prevent damaged cells from being destroyed and may facilitate development of met作者: emission 時(shí)間: 2025-4-1 22:25
Miloslava Plachkinova,Ken Peffers,Greg Moody tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer
